The inhibitory effects of the AR antagonist are dose-dependent with 80 μM enzalutamide exhibiting a significantly enhanced effects suppressing tumor sphere formation/CSC subpopulation in U87MG cell line compared with the negative control or lower concentration of enzalutamide (40 μM). The gene discussed is AR; the disease is neoplasm.